Odomzo

Sonidegib Instructions

Introduction: Sonidegib is a hedgehog signaling pathway inhibitor indicated for adult patients with locally advanced basal cell carcinoma (BCC) who have recurred after surgery or radiotherapy.

Drug name: sonidegib

Trade name: sonidegib

Brand: Odomzo

Unit: 300mg*30 tablets

China listing status: Sonidegib is not yet on the market

Target: Sonidegib target Hedgehog

Treatment: Sonidegib is suitable for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred after surgery or radiotherapy, or is not a candidate for surgery or radiotherapy.

Reference usage and dosage: The recommended dose of sonidegib is 200 mg orally once a day on an empty stomach, at least 1 hour before or 2 hours after a meal, and administered until disease progression or unacceptable toxicity. Confirm the pregnancy status of females of reproductive potential before starting Sonidegi. Serum creatine kinase (CK) levels and renal function tests were obtained in all patients before starting sonidegib. If a dose of Sonidegib is missed, resume dosing with the next scheduled dose

Adverse Reactions: The most common adverse reactions occurring in ≥10% of patients treated with Sonidegib 200 mg were muscle cramps, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, weight loss, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, and itching.

The above is the instructions for sonidegib. Please read it carefully and use it under the guidance of a physician.